AbbVie exceeded Q4 revenue and earnings estimates driven by strong growth in Rinvoq and Skyrizi.

From Nasdaq: 2025-02-03 21:32:37

AbbVie (NYSE: ABBV) exceeded Q4 revenue and earnings estimates, reporting sales of $15.1 billion and $2.16 per share, respectively. Strong growth for Rinvoq and Skyrizi contributed to the positive results and outlook. ABBV stock has underperformed the S&P 500 but offers upside potential, especially through a High-Quality portfolio.

In Q4, AbbVie’s revenue grew 5.6% year-over-year, with Skyrizi and Rinvoq sales offsetting declining Humira sales. Despite a 23% decline in earnings per share, the company expects strong growth with high single-digit revenue growth through 2029. The stock surged 5% post-earnings but has shown inconsistent returns over the last four years.

As ABBV stock trades at $184, slightly above its average P/S ratio, investors wonder about its future performance. With potential for growth, AbbVie’s valuation may justify further upside. Comparisons with peers and the Trefis Reinforced Value Portfolio show ABBV’s potential for increased returns. Invest with Trefis for market-beating portfolios and price estimates.



Read more at Nasdaq: What’s Next For ABBV Stock?